End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.08 USD | +6.05% | +9.96% | -6.27% |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 124.1 | 162.1 | - | - |
Enterprise Value (EV) 1 | 124.1 | 20.99 | 20.02 | 74.1 |
P/E ratio | -2.04 x | -2.47 x | -1.31 x | -0.95 x |
Yield | - | - | - | - |
Capitalization / Revenue | 62 x | - | - | - |
EV / Revenue | 62 x | - | - | - |
EV / EBITDA | - | - | - | - |
EV / FCF | - | - | - | - |
FCF Yield | - | - | - | - |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 22,896 | 31,914 | - | - |
Reference price 2 | 5.420 | 5.080 | 5.080 | 5.080 |
Announcement Date | 25/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | 2 | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | - | -30.74 | -59.25 | -143.5 | -209.5 |
Operating Margin | - | -1,537% | - | - | - |
Earnings before Tax (EBT) 1 | - | -27.88 | -61.05 | -119.1 | -186.7 |
Net income 1 | -30.5 | -27.88 | -61.05 | -120.1 | -187 |
Net margin | - | -1,393.8% | - | - | - |
EPS 2 | -165.3 | -2.660 | -2.055 | -3.892 | -5.360 |
Free Cash Flow | - | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 24/03/23 | 25/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | 2 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - |
EBIT 1 | -7.057 | -7.452 | -9.466 | -8.768 | -10.97 | -14.45 | -21.8 | -27.19 | -29.38 |
Operating Margin | - | -372.6% | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -6.785 | -6.353 | -8.151 | -6.629 | -11.49 | -16.52 | -26.42 | -27.19 | -29.38 |
Net income 1 | -6.785 | -6.353 | -8.151 | -6.629 | -11.49 | -16.52 | -26.42 | -27.19 | -29.38 |
Net margin | - | -317.65% | - | - | - | - | - | - | - |
EPS 2 | -35.80 | -0.3500 | - | -0.2300 | -0.3850 | -0.5500 | -0.8800 | -0.9300 | -1.000 |
Dividend per Share | - | - | - | - | - | - | - | - | - |
Announcement Date | 21/08/23 | 13/11/23 | 25/03/24 | 15/05/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - |
Net Cash position 1 | - | - | 141 | 142 | 88 |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex | - | - | - | - | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 24/03/23 | 25/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.27% | 162M | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+44.36% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |
- Stock Market
- Equities
- SGMT Stock
- Financials Sagimet Biosciences Inc.